0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SLAMF7

SLAMF7

Brief Information

Name:SLAM family member 7
Target Synonym:CS1,UNQ576/PRO1138,SLAMF7,Novel Ly9,SLAM Family Member 7,Membrane Protein FOAP-12,CD2 Subset 1,Protein 19A,CRACC,CD2-Like Receptor Activating Cytotoxic Cells,CD2-Like Receptor-Activating Cytotoxic Cells,19A24 Protein,CD319,19A,Novel LY9 (Lymphocyte Antige
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

SL7-HP2H3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

1e6 of the anti-SLAMF7 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human SLAMF7, His Tag (Cat. No. SL7-HP2H3) and negative control protein respectively, PE signals was used to evaluate the binding activity (QC tested).

SL7-HF2H7-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of Anti-SLAMF7 CAR-293 cells were stained with 100 μL of 10 μg/mL of FITC-Labeled Human SLAMF7, His Tag (Cat. No. SL7-HF2H7) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested)

SL7-H5256-ELISA
Human SLAMF7, Fc TagHuman SLAMF7, Fc Tag (Cat. No. SL7-H5256) ELISA bioactivity

Immobilized Human SLAMF7, Fc Tag (Cat. No. SL7-H5256) at 2 μg/mL (100 μL/well) can bind Humanized Anti-Human CS1 MAb with a linear range of 0.3-5 ng/mL (Routinely tested).

SL7-R52H7-MALS-HPLC
Rhesus macaque SLAMF7, His Tag (Cat. No. ) MALS images

The purity of Rhesus macaque SLAMF7, His Tag(Cat. No. SL7-R52H7) was more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.

  • Background
    SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Synonym Name

SLAMF7,CD319,CS1,CRACC,19A,FOAP-12

Background

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Elotuzumab PDL-063; HuLuc-63; BMS-901608 Approved Abbvie Inc, Bristol-Myers Squibb Company Empliciti Japan Multiple Myeloma s:28:"Bristol-Myers Squibb Company"; 2015-11-30 Smoldering Multiple Myeloma; Multiple Myeloma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CS1 Targeted CAR T-cells (Yake Biotechnology) Phase 1 Clinical Multiple Myeloma Details
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) Clinical Wuhan Bio-Raid Biotechnology, Tongji Hospital Hematologic Neoplasms Details
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Multiple Myeloma Details
UCART-CS1 UCART-38; UCART-CS1 Phase 1 Clinical Cellectis Multiple Myeloma Details
Anti-CD3/Anti-SLAMF7 Bispecific Antibody (University of Virginia) Phase 1 Clinical Multiple Myeloma Details

This web search service is supported by Google Inc.

totop